Commercial Insight: Top 20 Cancer Therapy Brands - Sales Of Targeted Therapies Overtake Cytotoxics In 2006 : Market Research Report

Commercial Insight: Top 20 Cancer Therapy Brands - Sales Of Targeted Therapies Overtake Cytotoxics In 2006

Published by: Datamonitor

Published: Jul. 2, 2007 - 221 Pages

ABOUT DATAMONITOR HEALTHCARE
About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Scope of the analysis; Datamonitor insight into the cancer market; Related reports; Upcoming reports
CHAPTER 2 MARKET OVERVIEW AND DYNAMICS: The Top 20 cancer therapy brands - 2006; The current market situation; The Top 20 cancer therapy brands - 2016; Sales by class; Molecular targeted therapies set to dominate over the forecast period; US; Japan; France; Germany; Italy; Spain; UK; 5EU; Seven major markets; Sales by country; Other countries slowly catching up with the lucrative US market; Brands by class and mode of action; Cytotoxic therapies still make up the majority of the forecasted cancer therapy brands; Brands by indication; Breast cancer drugs strongly dominate among the forecasted cancer therapy brands; Brands by company; AstraZeneca and Roche are behind the highest number of forecasted cancer therapy brands; Brands by event; Avastin set to experience the highest number of different events over the forecast period; Brands by compound annual growth rate; Molecular targeted therapies are driving the positive CAGR for the forecasted cancer therapy brands
CHAPTER 3 MARKET DEFINITION: Market definition for this report; Cytotoxic therapies; L1A - Alkylating agents; L1B - Antimetabolites; L1C - Vinca alkaloids and other plant-derived products; L1D - Antineoplastic antibiotics; L1X2 - Platinum compounds; Antihormonal therapies; L2A3 - Luteinizing hormone-releasing hormone analogs; L2B1 - Anti-estrogens; L2B2 - Anti-androgens; L2B3 - Aromatase inhibitors; Molecular targeted therapies; L1X3 - Antineoplastic monoclonal antibodies; L1X9 - All other antineoplastics
CHAPTER 4 COUNTRY MARKET ASSESSMENTS: Current and future opportunities and threats in the cancer market; Global opportunities and threats; Opportunities; Threats; US: opportunities and threats; Opportunities; Threats; Japan: opportunities and threats; Opportunities; Threats; 5EU: opportunities and threats; Opportunities; Threats; France: opportunities and threats; Opportunities; Threats; Germany: opportunities and threats; Opportunities; Threats; Italy: opportunities and threats; Opportunities; Threats; Spain: opportunities and threats; Opportunities; Threats; UK: opportunities and threats; Opportunities; Threats; Summary of environmental issues affecting the cancer market size
CHAPTER 5 FORECAST ANALYSIS: Country-specific assumptions and events; Effect of Medicare Modernization Act in the US; Biennial price cuts in Japan; Generic erosion assumptions; Product-specific assumptions and events; Cytotoxic therapies; Abraxane (ABX-007; Abraxis BioScience/AstraZeneca); Alimta (Pemetrexed; Eli Lilly); Camptosar/Campto (Irinotecan; Pfizer/Yakult/Daiichi); Doxil/Caelyx (Pegylated liposomal doxorubicin; Johnson & Johnson/Schering-Plough); Ellence/Farmorubicin (Epirubicin; Pfizer); Eloxatin (Oxaliplatin; Sanofi-Aventis); Furtulon (Doxifluridine; Roche/Chugai); Gemzar (Gemcitabine; Eli Lilly); Navelbine (Vinorelbine; Pierre Fabre/GlaxoSmithKline); Paraplatin (Carboplatin; Bristol-Myers Squibb); Taxol (Paclitaxel; Bristol-Myers Squibb); Taxotere (Docetaxel; Sanofi-Aventis); Temodar/Temodal (Temozolomide; Schering-Plough); TS-1 (Tegafur, gimeracil & oteracil; Taiho Pharmaceuticals/Sanofi-Aventis); UFT (Tegafur & uracil; Taiho Pharmaceuticals); Xeloda (Capecitabine; Roche); Antihormonal therapies; Arimidex (Anastrozole; AstraZeneca); Aromasin (Exemestane; Pfizer); Casodex (Bicalutamide; AstraZeneca); Femara (Letrozole; Novartis); Lupron (Leuprorelin; Takeda/TAP/Abbott/Wyeth); Nolvadex (Tamoxifen; AstraZeneca); Zoladex (Goserelin; AstraZeneca); Molecular targeted therapies; Avastin (Bevacizumab; Genentech/Roche); Erbitux (Cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono); Gleevec/Glivec (Imatinib; Novartis); Herceptin (Trastuzumab; Genentech/Roche); Iressa (Gefitinib; AstraZeneca); Nexavar (Sorafenib; Onyx Pharmaceuticals/Bayer Schering); Rituxan/MabThera (Rituximab; Biogen Idec/Genentech/Roche); Sutent (Sunitinib; Pfizer); Tarceva (Erlotinib; OSI Pharmaceuticals/Genentech/Roche); Tykerb (Lapatinib; GlaxoSmithKline); Vectibix (Panitumumab; Amgen); Velcade (Bortezomib; Ortho Biotech/Millennium Pharmaceuticals); Data definitions, limitations and assumptions; Standard units; Japanese market data; Derivation of sales forecasts and pricing trends; Forecasts; Forecast methodology
BIBLIOGRAPHY
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS: Cytotoxic therapies market data; Antihormonal therapies market data; Molecular targeted therapies market data
APPENDIX B - MARKET FORECAST DATA: US forecasts; Japan forecasts; France forecasts; Germany forecasts; Italy forecasts; Spain forecasts; UK forecasts; 5EU forecasts; Seven major market forecasts
APPENDIX C: Report methodology; About Datamonitor; About Datamonitor Healthcare; Disclaimer
List of Tables: Table 1: Top 20 cancer therapy brands in the US, Japan, Germany and France, 2006; Table 2: Top 20 cancer therapy brands in Italy, Spain, the UK, collective 5EU and collective seven major markets, 2006; Table 3: Newly marketed drugs included in the Top 20 cancer therapy brands, 2006-2017; Table 4: Seven major market sales of Top 20 cancer therapy brands by drug class, 2006; Table 5: Molecular targeted therapies included in the Top 20 cancer therapy brands, 2006; Table 6: Cytotoxic therapies included in the Top 20 cancer therapy brands, 2006; Table 7: Antihormonal therapies included in the Top 20 cancer therapy brands, 2006; Table 8: Top 20 cancer therapy brands in the US, Japan, Germany and France, 2016; Table 9: Top 20 cancer therapy brands in Italy, Spain, the UK, collective 5EU and collective seven major markets, 2006; Table 10: Forecasted cancer therapy brands by number of different events, 2007-2016; Table 11: Definition of the cancer market, 2007; Table 12: Abraxane: key facts; Table 13: Alimta: key facts; Table 14: Camptosar: key facts; Table 15: Doxil: key facts; Table 16: Ellence: key facts; Table 17: Eloxatin: key facts; Table 18: Furtulon: key facts; Table 19: Gemzar: key facts; Table 20: Navelbine: key facts; Table 21: Paraplatin: key facts; Table 22: Taxol: key facts; Table 23: Taxotere: key facts; Table 24: Market share of Taxotere, 2005; Table 25: Temodar: key facts; Table 26: TS-1: key facts; Table 27: UFT: key facts; Table 28: Xeloda: key facts; Table 29: Arimidex: key facts; Table 30: Aromasin: key facts; Table 31: Casodex: key facts; Table 32: Femara: key facts; Table 33: Lupron: key facts; Table 34: Nolvadex: key facts; Table 35: Zoladex: key facts; Table 36: Avastin: key facts; Table 37: Erbitux: key facts; Table 38: Gleevec: key facts; Table 39: Herceptin: key facts; Table 40: Iressa: key facts; Table 41: Nexavar: key facts; Table 42: Rituxan: key facts; Table 43: Approved indications for Rituxan in the US and EU, 2006; Table 44: Sutent: key facts; Table 45: Tarceva: key facts; Table 46: Tykerb: key facts; Table 47: Vectibix: key facts; Table 48: Velcade: key facts; Table 49: Abraxane: key facts; Table 50: Alimta: key facts; Table 51: Camptosar: key facts; Table 52: Doxil: key facts; Table 53: Ellence: key facts; Table 54: Eloxatin: key facts; Table 55: Furtulon: key facts; Table 56: Gemzar: key facts; Table 57: Navelbine: key facts; Table 58: Paraplatin: key facts; Table 59: Taxol: key facts; Table 60: Taxotere: key facts; Table 61: Temodar: key facts; Table 62: TS-1: key facts; Table 63: UFT: key facts; Table 64: Xeloda: key facts; Table 65: Arimidex: key facts; Table 66: Aromasin: key facts; Table 67: Casodex: key facts; Table 68: Femara: key facts; Table 69: Lupron: key facts; Table 70: Nolvadex: key facts; Table 71: Zoladex: key facts; Table 72: Avastin: key facts; Table 73: Erbitux: key facts; Table 74: Gleevec: key facts; Table 75: Herceptin: key facts; Table 76: Iressa: key facts; Table 77: Nexavar: key facts; Table 78: Rituxan: key facts; Table 79: Sutent: key facts; Table 80: Tarceva: key facts

Abstract

Introduction

Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.

Scope

Overview of the current Top 20 cancer therapy brands market Individual country, 5EU and seven-market sales forecasts from 2006 to 2016 for the leading cancer therapy brands Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events Detailed product profiles and discussion of assumptions and events used in forecast analysis

Highlights

Four newly marketed drugs are expected to become part of the Top 20 cancer therapies during the forecast period: Sutent (sunitinib; Pfizer), Nexavar (sorafenib; Onyx/Bayer), Vectibix (panitumumab; Amgen) and Tykerb (lapatinib; GSK). These products combined with the existing Top 20 cancer therapies are set to reach $52.7 billion in sales by 2016. The Top 20 cancer therapy brands are forecast to experience 144 different events between 2007 and 2016. Considering the fact that many of these events will take place in each of the seven major markets, Datamonitor expects the Top 20 cancer therapy brands to experience 792 events across the 7MM. The 35 drugs that make up the Top 20 cancer therapy brands have gained approval in 18 different tumor types. Three of the 'big four' tumor types boast the highest number of leading cancer therapy brands namely: breast cancer with 18 of the 35 forecasted drugs, non-small cell lung cancer with eight, and colorectal cancer with seven.

Reasons to Purchase

Understand market specific drivers and predict the future potential of key cancer therapy brands Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands

Please Note: This product is delivered as a zip file,which contains Excel and PDF files.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Top 20 Cancer Therapy Brands - Sales Of Targeted Therapies Overtake Cytotoxics In 2006

Table of Contents

Abstract